Cargando…
Comparison of 12-Week Additional Effect Features of Formoterol Co-Inhalation and Tulobuterol Patch on Budesonide Inhalation in Elderly Patients With Asthma
BACKGROUND: For asthma strategy, to avoid the aggravation of bronchial inflammation and contraction, the long acting beta agonist (LABA) addition on inhaled corticosteroids (ICS) has been recommended. OBJECTIVES: To know whether there is any clinical difference between the additional efficacies of F...
Autores principales: | Fukahori, Susumu, Kawano, Tetsuya, Obase, Yasushi, Iriki, Jun, Tsuchida-Yabe, Tomoko, Tomari, Shinya, Fukushima, Chizu, Matsuse, Hiroto, Mukae, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739199/ https://www.ncbi.nlm.nih.gov/pubmed/33403154 http://dx.doi.org/10.1177/2152656720980416 |
Ejemplares similares
-
Regulation of dendritic cell functions against harmful respiratory pathogens by a cysteinyl leukotrienes receptor antagonist
por: Matsuse, Hiroto, et al.
Publicado: (2012) -
Retrospective cohort study of leukotriene receptor antagonist therapy for preventing upper respiratory infection-induced acute asthma exacerbations
por: Matsuse, Hiroto, et al.
Publicado: (2013) -
Budesonide–formoterol (inhalation powder) in the treatment of COPD
por: Ceylan, Erkan
Publicado: (2006) -
Cysteinyl leukotriene receptor antagonist regulates allergic airway inflammation in an organ- and cytokine-specific manner
por: Kawano, Tetsuya, et al.
Publicado: (2014) -
Long-term maintenance of pediatric asthma: focus on budesonide/formoterol inhalation aerosol
por: Huynh, Peter N, et al.
Publicado: (2010)